- CA$27.80m
- CA$31.70m
- $14.52m
- 57
- 48
- 29
- 41
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.99 | ||
Price to Tang. Book | 4.76 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1.19 | ||
EV to EBITDA | 39.43 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -7.53% | ||
Return on Equity | -14.52% | ||
Operating Margin | -3.76% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 11.15 | 8.65 | 10.54 | 14.88 | 14.52 | n/a | n/a | 10.83% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Aurora Spine Corporation is a designer and manufacturer of medical devices. The Company is engaged in the development and distribution of minimally invasive, interspinous fusion systems and devices. It offers a range of devices specifically designed to address cervical spine conditions and restore optimal functionality. Its Cervical product line includes apollo, Discovery, and DEXA-C. The apollo Anterior Cervical Plate system is comprised of cervical plates and bone screws constructed of titanium alloy as described by ASTM F136. Discovery is its Spine's invasive cervical interbody fusion system. The DEXA-C is crafted to mimic the lattice structure of cancellous bone in humans while maintaining a comparable modulus of elasticity. The Company has established a physician training program through national and regional cadaver labs.
Directors
- Trent Northcutt PRE (52)
- Chad Clouse CFO
- Laszlo Garamszegi CTO
- David Meyer VPR
- Tracy Graf IND (55)
- J. Daryl MacLellan IND
- David Rosenkrantz IND (63)
- Michael Seid IND
- James Snow IND
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- July 4th, 2013
- Public Since
- September 10th, 2013
- No. of Employees
- 13
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
TSX Venture Exchange
- Shares in Issue
- 77,219,784

- Address
- 20 HOLLY STREET, SUITE 300, TORONTO, M4S 3B1
- Web
- https://www.aurora-spine.com/
- Phone
- +1 7604242004
- Auditors
- MNP LLP
Upcoming Events for ASG
Q1 2025 Aurora Spine Corp Earnings Release
Aurora Spine Corp Annual Shareholders Meeting
Q2 2025 Aurora Spine Corp Earnings Release
Q3 2025 Aurora Spine Corp Earnings Release
Similar to ASG
CardioComm Solutions
TSX Venture Exchange
Conavi Medical
TSX Venture Exchange
Covalon Technologies
TSX Venture Exchange
EvokAI Creative Labs
TSX Venture Exchange
Evome Medical Technologies
TSX Venture Exchange
FAQ
As of Today at 24:18 UTC, shares in Aurora Spine are trading at CA$0.36. This share price information is delayed by 15 minutes.
Shares in Aurora Spine last closed at CA$0.36 and the price had moved by +20% over the past 365 days. In terms of relative price strength the Aurora Spine share price has outperformed the Toronto Stock Exchange 300 Composite Index by +6.69% over the past year.
There is no consensus recommendation for this security.
Find out moreAurora Spine does not currently pay a dividend.
Aurora Spine does not currently pay a dividend.
Aurora Spine does not currently pay a dividend.
To buy shares in Aurora Spine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.36, shares in Aurora Spine had a market capitalisation of CA$27.80m.
Here are the trading details for Aurora Spine:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: ASG
Based on an overall assessment of its quality, value and momentum Aurora Spine is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aurora Spine. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -23.03%.
As of the last closing price of CA$0.36, shares in Aurora Spine were trading +4.48% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Aurora Spine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Aurora Spine's management team is headed by:
- Trent Northcutt - PRE
- Chad Clouse - CFO
- Laszlo Garamszegi - CTO
- David Meyer - VPR
- Tracy Graf - IND
- J. Daryl MacLellan - IND
- David Rosenkrantz - IND
- Michael Seid - IND
- James Snow - IND